Diabetes Core Update – August 2019
Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association’s four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 20 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatmen...
Source: Diabetes Core Update - July 24, 2019 Category: Endocrinology Authors: American Diabetes Association Source Type: podcasts
FDA Drug Safety Podcast: Updated FDA review concludes that use of pioglitazone may be linked to an increased risk of bladder cancer
(Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - February 9, 2019 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
Diabetes Core Update - November 2017
Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association’s four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 15 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatmen...
Source: Diabetes Core Update - October 24, 2017 Category: Endocrinology Authors: American Diabetes Association Source Type: podcasts
FDA Drug Safety Podcast: Updated FDA review concludes that use of pioglitazone may be linked to an increased risk of bladder cancer
On December 12, 2016, FDA announced as a result of an updated review, that it has concluded that use of the type 2 diabetes medicine pioglitazone (brand names Actos, Actoplus Met, Actoplus Met XR, Duetact, Oseni) may be linked to an increased risk of bladder cancer. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - March 9, 2017 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
Is the Diabetes 'Holy Grail' in Reach?
With empagliflozin, pioglitazone, and liraglutide, we may finally be getting closer to the 'holy grail' of a diabetes drug that also has cardiovascular benefits. (Source: Medscape Diabetes & Endocrinology Podcast)
Source: Medscape Diabetes & Endocrinology Podcast - May 11, 2016 Category: Endocrinology Authors: Medscape Source Type: podcasts
Feb 19 Cardiology News
Carotid stenting vs surgery, leadless pacing, the CMS decision on Watchman, pioglitazone after stroke, and subretinal bleeding with antithrombins are discussed by Dr John Mandrola this week. (Source: Medscape Cardiology Podcast)
Source: Medscape Cardiology Podcast - February 19, 2016 Category: Cardiology Authors: Medscape Source Type: podcasts
Clinical Trials on Pioglitazone
Dr. Dana King, professor in the Department of Family Medicine, discusses a new clinical trial being conducted to determine the effect of a drug known as pioglitazone on ADMA levels, which has found to be a risk factor for heart disease among diabetes patients. He explains that pioglitazone is already an approved drug for the treatment of diabetes, and that this research is being conducted to determine what added benefits the drug may have. Dr. King provides a description of exactly how this study is conducted on the patient’s part, and the benefits associated with it. (Source: MUSC Heart and Vascular Podcast)
Source: MUSC Heart and Vascular Podcast - December 3, 2014 Category: Cardiology Authors: Medical University of South Carolina Source Type: podcasts
